Celerion Collaborates with South Korea to Strengthen Early Phase Clinical Research
Celerion and the Korean Drug Development Fund announced a formal collaboration
Celerion and the Korean Drug Development Fund (KDDF) announced a formal collaboration to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea. The agreement—in the form of a Memorandum of Understanding (MOU)—provides the framework for collaborations of mutual benefit to both organizations. Companies funded by KDDF will have access to Celerion’s experience and expertise in early clinical research and bioanalysis, as well as the global footprint of external partner sites. The collaboration will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
